Last reviewed · How we verify
GSK2330672
At a glance
| Generic name | GSK2330672 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN) (PHASE3)
- Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls (PHASE1)
- Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis (PHASE2)
- Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects (PHASE1)
- Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat (PHASE1)
- A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients (PHASE2)
- Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin (PHASE2)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2330672 CI brief — competitive landscape report
- GSK2330672 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI